EBNA2 and activated notch induce expression of BATF

Journal of Virology

Volumn 77, Issue 10, 2003, Pages 6029-6040

  Johansen, Lisa M ^a,c   Deppmann, Christopher D ^a   Erickson, Kimberly D ^b,d   Coffin III, William F ^b   Thornton, Tina M ^a   Humphrey, Sean E ^a   Martin, Jennifer M ^b   Taparowsky, Elizabeth J ^a  

^a PURDUE UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Department of Preclinical Development and Formulations   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NOTCH RECEPTOR; NUCLEAR PROTEIN; PROTEIN EBNA2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR BATF; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; B LYMPHOCYTE; CELL GROWTH; CELL SPECIFICITY; CONTROLLED STUDY; CYTOLYSIS; EPSTEIN BARR VIRUS; GENE ACTIVATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE TARGETING; GENETIC CODE; GROWTH INHIBITION; HUMAN; HUMAN CELL; LATENT PERIOD; MAMMAL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; REPORTER GENE; TRANSACTIVATION; UPREGULATION; VIRUS CELL INTERACTION; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS REPLICATION;

B-LYMPHOCYTES; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL LINE; CELLS, CULTURED; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GENE EXPRESSION REGULATION, VIRAL; HELA CELLS; HERPESVIRUS 4, HUMAN; HUMANS; MEMBRANE PROTEINS; RECEPTORS, NOTCH; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; VIRAL PROTEINS; VIRUS LATENCY;

EID: 0038032828     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.10.6029-6040.2003     Document Type: Article

References (83)

1. Abbot, S. D., M. Rowe, K. Cadwallader, A. Ricksten, J. Gordon, F. Wang, L. Rymo, and A. B. Rickinson. 1990. Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein. J. Virol. 64:2126-2134.
2. Artavanis-Tsakonas, S., M. D. Rand, and R. J. Lake. 1999. Notch signaling: cell fate control and signal integration in development. Science 284:770-776.
3. Baichwal, V. R., and B. Sugden. 1989. Transformation of Balb/c 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. Oncogene 2:461-467.
4. Ben-Bassat, H., N. Goldblum, S. Mitrani, T. Goldblum, J. M. Yoffey, M. M. Cohen, Z. Bentwich, B. Ramot, E. Klein, and G. Klein. 1977. Establishment in continuous culture of a new type of lymphocyte from a "Burkitt-like" malignant lymphoma (line D.G.-75). Int. J. Cancer 19:27-33.
5. Cohen, J., F. Wang, J. Mannick, and E. Kieff. 1989. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc. Natl. Acad. Sci. USA 86:9558-9562.
6. Cohen, J., and E. Kieff. 1991. An Epstein-Barr virus nuclear protein 2 domain essential for transformation is a direct transcriptional activator. J. Virol. 65:5880-5885.
7. Cohen, J., F. Wang, and E. Kieff. 1991. Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. J. Virol. 65:2545-2554.
8. Cordier, M., A. Calender, M. Billaud, U. Zimber, G. Rousselet, O. Pavlish, J. Banchereau, T. Tursz, G. W. Bornkamm, and G. M. Lenoir. 1990. Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23. J. Virol. 64:1002-1013.
9. Dorsey, M. J., H.-J. Tae, K. G. Sollenberger, N. T. Mascarenhas, L. M. Johansen, and E. J. Taparowsky. 1995. B-ATF: a novel human bZIP protein that associates with members of the AP-1 transcription factor complex. Oncogene 11:2255-2265.
10. Echlin, D., H.-J. Tae, N. Mitin, and E. J. Taparowsky. 2000. B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos. Oncogene 19:1752-1763.
11. Erickson, K. D., and J. M. Martin. 1997. Early detection of the lytic LMP-1 protein in EBV-infected B-cells suggests its presence in the virion. Virology 234:1-13.
12. Fahraeus, R., A. Jansson, A. Ricksten, A. Sjoblom, and L. Rymo. 1990. Epstein-Barr virus-encoded nuclear antigen 2 activates the latent membrane protein promoter by modulating the activity of a negative regulatory element. Proc. Natl. Acad. Sci. USA 87:7390-7394.
13. Farrell, P. J., D. T. Rowe, C. M. Rooney, and T. Kouzarides. 1989. Epstein-Barr virus BZLF1 transctivator specifically binds to a consensus AP-1 site and is related to c-fos. EMBO J. 8:127-133.
14. Flemington, E., and S. H. Speck. 1990. Identification of phorbol ester response elements in the promoter of the Epstein-Barr virus putative lytic switch gene BZLF1. J. Virol. 64:1217-1226.
15. Fuentes-Panana, E. M., R. Peng, G. Brewer, J. Tan, and P. D. Ling. 2000. Regulation of the Epstein-Barr C promoter by AUF1 and the cyclic AMP protein kinase A signaling pathway. J. Virol. 74:8166-8175.
16. Gordadze, A. V., R. Peng, J. Tan, G. Liu, R. Sutton, B. Kempkes, G. W. Bornkamn, and P. D. Ling. 2001. NotchlIC partially replaces EBNA2 function in B cells immortalized by Epstein-Barr virus. J. Virol. 75:5899-5912.
17. Grossman, S., E. Johannsen, X. Tong, R. Yalamanchili, and E. Kieff. 1994. The Epstein-Barr virus nuclear protein 2 transactivator is directed to response elements by the Jk recombination signal binding protein. Proc. Natl. Acad. Sci. USA 91:7568-7572.
18. Hammerschmidt, W., and B. Sugden. 1989. Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature 340:393-397.
19. Harada, S., and E. Kieff. 1997. Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation. J. Virol. 71:6611-6618.
20. Hasegawa, H., Y. Utsunomiya, K. Kishimoto, Y. Tange, M. Yasukawa, and S. Fujita. 1996. SFA-2, a novel bZIP transcription factor induced by human T-cell leukemia virus type 1, is highly expressed in mature lymphocytes. Biochem. Biophys. Res. Commun. 222:164-170.
21. κ. Science 265:92-95.
22. Höfelmayr, H., L. J. Strobl, G. Marschall, G. W. Bornkamn, and U. Zimber-Strobl. 2001. Activated Notchl can transiently substitute for EBNA2 in the maintenance of proliferation of LMP1-expressing immortalized B cells. J. Virol. 75:2033-2040.
23. Höfelmayr H., L. J. Strobl, C. Stein, G. Laux, G. Marschall, G. W. Bornkamm, and U. Zimber-Strobl. 1999. Activated mouse Notch1 transactivates Epstein-Barr virus nuclear antigen 2-regulated viral promoters. J. Virol. 73:2770-2780.
24. Holley-Guthrie, E. A., E. B. Quinlivan, E.-C. Mar, and S. Kenney. 1990. The Epstein-Barr virus (EBV) BMRF 1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner. J. Virol. 64:3753-3759.
25. Hsieh, J. J.-D., and S. D. Hayward. 1995. Masking of the CBF1/RBP-JK transcriptional repression domain by Epstein-Barr virus EBNA2. Science 268:560-563.
26. Hsieh, J. J.-D., T. Henkel, P. Salmon, E. Robey, M. G. Peterson, and S. D. Hayward. 1996. Truncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2. Mol. Cell. Biol. 16:952-959.
27. Hsieh, J. J.-D., D. E. Nofziger, G. Weinmaster, and S. D. Hayward. 1997. Epstein-Barr virus immortalization: Notch2 interacts with CBF1 and blocks differentiation. J. Virol. 71:1938-1945.
28. Hsieh, J. J., S. Zhou, L. Chen, D. B. Young, and S. D. Hayward. 1999. CIR, a corepressor linking the DNA binding factor CBF1 to the histone deacetylase complex. Proc. Natl. Acad. Sci. USA 96:23-28.
29. Jeffries, S., and A. J. Capobianco. 2000. Neoplastic transformation by Notch requires nuclear localization. Mol. Cell. Biol. 20:3928-3941.
30. Jochner, N., D. Eick, U. Zimber-Strobl, M. Pawlita, G. W. Bornkamm, and B. Kempkes. 1996. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin μ gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells. EMBO J. 15:375-382.
31. Johannsen, E., E. Koh, G. Mosialos, X. Tong, E. Kieff, and E. Grossman. 1995. Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by Jκ and PU.1. J. Virol. 69:253-262.
32. Kaiser, C., G. Laux, D. Eick, N. Jochner, G. W. Bornkamm, and B. Kempkes. 1999. The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J. Virol. 73:4481-4484.
33. Kaiser, C., O. vonStein, G. Laux, and M. Hoffmann. 1999. Functional genomics in cancer research: identification of target genes of the Epstein-Barr virus nuclear antigen 2 by subtractive cDNA cloning and high-throughput differential screening using high-density agarose gels. Electrophoresis 20:261-268.
34. Kaye, K. M., K. M. Izumi, and E. Kieff. 1993. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc. Natl. Acad. Sci. USA 90:9150-9154.
35. Kieff, E. 1996. Epstein-Barr virus and its replication, p. 1109-1162. In Fundamental virology, B. N. Fields, D. M. Knipe, and P. M. Howley (ed.). Lippincott-Raven, Philadelphia, Pa.
36. Klein, G., T. Lindahl, M. Jondal, W. Leibold, J. Menezes, K. Nilsson, and C. Sundstrom. 1974. Continuous lymphoid cell lines with characteristics of B cells (bone-marrow-derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas. Proc. Natl. Acad. Sci. USA 71:3283-3286.
37. Knecht, H., C. Berger, A. S. Al-Homsi, C. McQuain, and P. Brousset. 1997. Epstein-Barr virus oncogenesis. CRC Crit. Rev. Oncol.-Hematol. 26:117-135.
38. Knutson, J. C. 1990. The level of c-fgr RNA is increased by EBNA2, an Epstein-Barr virus gene required for B-cell immortalization. J. Virol. 64:2530-2536.
39. Lassar, A. B., R. L. Davis, W. E. Wright, T. Kadesch, C. Murre, A. Voronova, D. Baltimore, and H. Weintraub. 1991. Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo. Cell 66:305-315.
40. Laux, G., B. Adam, L. J. Strobl, and F. Moreau-Gachelin. 1994. The Spi1/PU.1 and Spi-B ets family transcription factors and the recombination signal binding protein RBP-Jκ interact with an Epstein-Barr nuclear antigen 2 responsive cis-element. EMBO J. 13:5624-5632.
41. Li, J., G. W. Peet, D. Balzarano, X. Li, P. Massa, R. W. Barton, and K. Marcu. 2001. Novel NEMO/IκB kinase and NF-κB target genes at the pre-B to immature B cell transition. J. Biol. Chem. 276:18579-18590.
42. Ling, P. D., D. R. Rawlins, and S. D. Hayward. 1993. The Epstein-Barr virus immortalizing protein EBNA-2 is targeted to DNA by a cellular enhancerbinding protein. Proc. Natl. Acad. Sci. USA 90:9237-9241.
43. Ling, P. D., J. J.-D. Hsieh, I. K. Ruf, D. R. Rawlins, and S. D. Hayward. 1994. EBNA-2 upregulation of Epstein-Barr virus latency promoters and the cellular CD23 promoter utilizes a common targeting intermediate, CBF1. J. Virol. 68:5375-5383.
44. Liu, P., S. Liu, and S. H. Speck. 1998. Identification of a negative cis-element within the ZII domain of the Epstein-Barr virus lytic switch BZLF1 gene promoter. J. Virol. 72:8230-8239.
45. Lu, F. M., and S. E. Lux. 1996. Constitutively active human Notchl binds to the transcription factor CBF 1 and stimulates transcription through a promoter containing a CBF 1-responsive element. Proc. Natl. Acad. Sci. USA 93:5663-5667.
46. MacCallum, P., L. Karimi, and L. J. Nicholson. 1999. Definition of the transcription factors which bind the differentiation responsive element of the Epstein-Barr virus BZLF1 Z promoter in human epithelial cells. J. Gen. Virol. 80:1501-1512.
47. Martin, J., and B. Sugden. 1991. Transformation by the oncogenic latent membrane protein correlates with its rapid turnover, membrane localization, and cytoskeletal association. J. Virol. 65:3246-3258.
48. Meyer, N. P., L. M. Johansen, H.-J. Tae, P. P. Budde, K. L. Williams, and E. J. Taparowsky. 1998. Genomic organization of human B-ATF, a target for regulation by EBV and HTLV-1. Mamm. Genome 9:849-852.
49. 2 repeat domain. J. Virol. 71:6619-6628.
50. Nye, J. S., R. Kopan, and R. Axel. 1994. An activated Notch suppresses neurogenesis and myogenesis but not gliogenesis in mammalian cells. Development 120:2421-2430.
51. Osborne, B., and L. Miele. 1999. Notch and the immune system. Immunity 11:653-663.
52. Peng, R., J. Tan, and P. D. Ling. 2000. Conserved regions in the Epstein-Barr virus leader protein define distinct domains required for nuclear localization and transcriptional cooperation with EBNA2. J. Virol. 74:9953-9963.
53. Peters, M. A., K. G. Sollenberger, T.-L. Kao, and E. J. Taparowsky. 1997. A minimal regulatory region maintains constitutive expression of the max gene. Mol. Cell. Biol. 17:1037-1048.
54. Price, T., J. Altken, and E. R. Simpson. 1992. Relative expression of aromatase cytochrome p450 in human fetal tissues as determined by competitive polymerase chain amplification. J. Clin. Endocrinol. Metab. 74:879-883.
55. Quinlivan, E. B., E. A. Holley-Guthrie, M. Norris, D. Gutsch, S. L. Bachenheimer, and S. C. Kenney. 1993. Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1. Nucleic Acids Res. 21:1999-2007.
56. Rabson, M., L. Heston, and G. Miller. 1983. Identification of a rare Epstein-Barr virus variant that enhances early antigen expression in Raji cells. Proc. Natl. Acad. Sci. USA 80:2762-2766.
57. Ramocki, M. B., S. E. Johnson, M. A. White, C. L. Ashendel, S. F. Konieczny, and E. J. Taparowsky. 1997. Signaling through MAP kinase and Rac/Rho does not duplicate the effects of activated Ras on skeletal myogenesis. Mol. Cell. Biol. 17:3547-3555.
58. Reedman, B. M., and G. Klein. 1973. Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and nonproducer lymphoblastoid cell lines. Int. J. Cancer 11:499-520.
59. Rickinson, A. B., and E. Kieff. 1996. Epstein-Barr virus, p.2397-2446. In Fields virology, B. N. Fields, D. M. Knipe, and P. M. Howley (ed.). Lippincott-Raven, Philadelphia, Pa.
60. Ruf, I. K., and D. R. Rawlins. 1995. Identification and characterization of ZIIBC, a complex formed by cellular factors and the ZII site of the Epstein-Barr virus BZLF1 promoter. J. Virol. 69:7648-7657.
61. Sakai, T., Y. Taniguchi, K. Tamura, S. Minoguchi, T. Fukuhara, L. J. Strobl, U. Zimber-Strobl, G. W. Bornkamm, and T. Honjo. 1998. Functional replacement of the intracellular region of the Notchl receptor by Epstein-Barr virus nuclear antigen 2. J. Virol. 72:6034-6039.
62. Sample, J., L. Young, B. Martin, T. Chatman, E. Kieff, A. Rickinson, and E. Kieff. 1990. Epstein-Barr viruses types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J. Virol. 64:4084-4092.
63. Severson, C. D., D. L. Burg, D. E. Lafrenz, and T. L. Feldbush. 1987. An alternative method of panning for rat B lymphocytes. Immunol. Lett. 15:291-295.
64. Shaulian, E., and M. Karin. 2002. AP-1 as a regulator of cell life and death. Nat. Cell. Biol. 4:131-136.
65. Shimizu, Y., D. E. Geraghty, B. H. Koller, H. T. Orr, and R. DeMars. 1988. Transfer and expression of three cloned human non-HLA-A,B,C class I major histocompatibility complex genes in mutant lymphoblastoid cells. Proc. Natl. Acad. Sci. USA 85:227-231.
66. Sinclair, A. J., and P. J. Farrell. 1992. Epstein-Barr virus transcription factors. Cell Growth Diff. 3:557-563.
67. 1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J. 13:3321-3328.
68. Speck, S. H., T. Chatila, and E. Flemington. 1997. Reactivation of Epstein-Barr virus: regulation and function of the BZLF1 gene. Trends Microbiol. 5:399-405.
69. Spender, L. C., G. H. Cornish, B. Rowland, B. Kempkes, and P. J. Farell. 2001. Direct and indirect regulation of cytokine and cell cycle proteins by EBNA-2 during Epstein-Barr virus infection. J. Virol. 75:3537-3546.
70. Strobl, L. J., H. Höfelmayr, C. Stein, G. Marschall, M. Brielmeier, G. Laux, G. W. Bornkamm, and U. Zimber-Strobl. 1997. Both Epstein-Barr viral nuclear antigen 2 (EBNA2) and activated Notchl transactivate genes by interacting with the cellular protein RBP-JK. Immunobiology 198:299-306.
71. Strobl, L. J., H. Höfelmayr, G. Marschall, M. Brielmeier, G. W. Bornkamm, and U. Zimber-Strobl. 2000. Activated Notch modulates gene expression in B cells similarly to Epstein-Barr viral nuclear antigen 2. J. Virol. 74:1727-1735.
72. Tamura, K., Y. Taniguchi, S. Minoguchi, T. Sakai, T. Tun, T. Furukawa, and T. Honjo. 1995. Physical interaction between a novel domain of the receptor Notch and the transcription factor RBP-Jκ/Su(H). Curr. Biol. 5:1416-1423.
73. Tomkinson, B., E. Robertson, and E. Kieff. 1993. Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J. Virol. 67:2014-2025.
74. Waltzer, L., C. Logeat, C. Brou, A. Israel, A. Sergeant, and E. Manet. 1994. The human J kappa recombination signal sequence binding protein (RBP-J kappa) targets the Epstein-Barr virus EBNA2 protein to its DNA responsive elements. EMBO J. 13:5633-5638.
75. Wang, D., D. Liebowitz, and E. Kieff. 1985. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43:831-840.
76. Wang, F., S. Tsang, M. Kurilla, J. Cohne, and E. Kieff. 1990. Epstein-Barr virus nuclear antigen 2 transactivates the latent membrane protein (LMP1). J. Virol. 64:3407-3416.
77. Wang, Y.-C. J., J.-M. Huang, and E. A. Montalvo. 1997. Characterization of proteins binding to the ZII element in the Epstein-Barr virus BZLF1 promoter: transactivation by ATF1. Virology 227:323-330.
78. Weinmaster, G., V. J. Roberts, and G. Lemke. 1992. Notch2: a second mammalian Notch gene. Development 116:931-941.
79. Williams, K. L., I. Nanda, G. E. Lyons, C. T. Kuo, M. Schmid, J. M. Leiden, M. H. Kaplan, and E. J. Taparowsky. 2001. Characterization of murine BATF: a negative regulator of activator protein-1 activity in the thymus. Eur. J. Immunol. 31:1620-1627.
80. Yalamanchili, R., X. Tong, S. Grossman, E. Johannsen, G. Mosialos, and E. Kieff. 1994. Genetic and biochemical evidence that EBNA 2 interaction with a 63-kDa cellular GTG-binding protein is essential for B lymphocyte growth transformation by EBV. Virology 204:634-641.
81. Zhang, Q., D. Gutsch, and S. Kenney. 1994. Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol. Cell. Biol. 14:1929-1938.
82. Zhou, S., M. Fujimuro, J. J. Hseih, L. Chen, and S. D. Hayward. 2000. A role for SKIP in EBNA2 activation of CBF1-repressed promoters. J. Virol. 74:1939-1947.
83. Zimber-Strobl, U., L. J. Strobl, C. Meitinger, R. Hinrichs, T. Sakai, T. Furukawa, T. Honjo, and G. W. Bornkamm. 1994. Eppstein-Barr virus nuclear antigen 2 exerts its transactivating function through interaction with recombination signal binding protein RBP-J kappa, the homologue of Drosophila Suppressor of Hairless. EMBO J. 13:4973-4982.